Engineering Functional Biologics with Structure-Based Grafting to Unlock Antibodies to go Beyond Binding & Actively Modulate Biology

• Explore structure-guided strategies to engineer antibodies and biologics that move beyond passive binding to actively modulate biological pathways
• Leverage structural insights to optimize stability, specificity, and functionality across complex or traditionally intractable targets
• Discuss emerging design principles and case studies showcasing functional biologics with enhanced therapeutic potential

Speakers:

Glen Spraggon

Executive Director

Novartis